Your browser doesn't support javascript.
loading
Omalizumab in asthma: an update on recent developments.
Humbert, Marc; Busse, William; Hanania, Nicola A; Lowe, Philip J; Canvin, Janice; Erpenbeck, Veit J; Holgate, Stephen.
Afiliação
  • Humbert M; Service de Pneumologie University Paris-Sud, Inserm U999, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. Electronic address: marc.humbert@bct.aphp.fr.
  • Busse W; Department of Medicine, University of Wisconsin Medical School, Madison, Wis.
  • Hanania NA; Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas.
  • Lowe PJ; Advanced Quantitative Sciences, Novartis Pharma AG, Basel, Switzerland.
  • Canvin J; Novartis Pharmaceuticals UK Limited, Clinical Research, Horsham, West Sussex, UK.
  • Erpenbeck VJ; Translational Medicine, Respiratory Profiling, Novartis Pharma AG, Basel, Switzerland.
  • Holgate S; University of Southampton, Faculty of Medicine, Southampton General Hospital, Southampton, UK.
J Allergy Clin Immunol Pract ; 2(5): 525-36.e1, 2014.
Article em En | MEDLINE | ID: mdl-25213045
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Anticorpos Anti-Idiotípicos / Antiasmáticos / Antialérgicos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Anticorpos Anti-Idiotípicos / Antiasmáticos / Antialérgicos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2014 Tipo de documento: Article